
Wockhardt Limited has informed the Exchange regarding a press release dated December 11, 2023, titled "Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873.".
Filed with NSE · · 3 pages · English
The study demonstrated that a three-day treatment with Nafithromycin is as effective as a seven-day treatment with Moxifloxacin, showing a high clinical cure rate. The study reported no serious adverse events, indicating that Nafithromycin is safe for community use against resistant organisms.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Wockhardt Limited has informed the Exchange regarding a press release dated December 11, 2023, titled "Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873.".
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt